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Biomarkers of immunotherapy in urothelial
and renal cell carcinoma: PD-L1, tumor
mutational burden, and beyond
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and Tian Zhang2*
Abstract
Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic
urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed
to predict for treatment response. Immunohistochemical quantification of PD-L1 was developed as a promising biomarker
in early clinical trials, but many shortcomings of the four different assays (different antibodies, disparate cellular populations,
and different thresholds of positivity) have limited its clinical utility. Further limitations include the use of archival specimens
to measure this dynamic biomarker. Indeed, until PD-L1 testing is standardized and can consistently predict treatment
outcome, the currently available PD-L1 assays are not clinically useful in urothelial and renal cell carcinoma. Other more
promising biomarkers include tumor mutational burden, profiles of tumor infiltrating lymphocytes, molecular subtypes, and
PD-L2. Potentially, a composite biomarker may be best but will need prospective testing to validate such a biomarker.
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Background
Over the past few years, immune checkpoint inhibitors
(CPIs) blocking the programmed cell death receptor 1
(PD-1) pathway have emerged as treatments capable of
improving the overall survival of patients with metastatic
renal cell carcinoma (mRCC) and metastatic urothelial
carcinoma (mUC) [1, 2]. Based on promising phase II
and III clinical trials, the United States Food and Drug
Administration (FDA) has approved nivolumab for renal
cell carcinoma [2] and five PD-1/PD-L1 inhibitors
(atezolizumab, pembrolizumab, nivolumab, durvalumab,
and avelumab) for urothelial cancer [2, 3]. Due to
relatively modest objective response rates (approximately
25% in mRCC and 15–21% in mUC), it is important to
identify biomarkers predictive of response or resistance
to immunotherapy [1, 3–5]. An ideal, clinically useful,
predictive biomarker would dichotomize patients as po-
tential responders or non-responders based on a positive
or negative result. Moreover, an ideal biomarker assay
would be consistent in its performance and threshold
for defining a positive result. During clinical develop-
ment of these CPIs, tissue-based assays for PD-L1 have
been developed in parallel as a potential companion
biomarker for CPI response.
PD-L1 is one of several ligands for the PD-1 receptor,
and early trials in advanced mUC suggested that immuno-
histochemistry (IHC) staining for PD-L1 on paraffin-
embedded tumor specimens would serve as a predictive
biomarker [3, 6]. Based on this data, the FDA approved a
companion PD-L1 assay (Ventana) in parallel with the
approval of atezolizumab for mUC. However, with other
clinical trials maturing, IHC staining for PD-L1 status has
not fulfilled its promise as a predictive biomarker. Indeed,
each PD-1/PD-L1 targeting therapeutic has been developed
with its own PD-L1 companion diagnostic antibody,
thereby limiting the clinical interpretation of PD-L1 status.
In this review, we examine the characteristics of IHC
staining for PD-L1 as a biomarker in both mUC and
mRCC, as well as alternative predictive biomarkers which
are currently in development. For convenience of compari-
son, we use objective response rates (ORR) defined as the
rate of partial and complete responses, to discuss the
treatment response across trials.
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Urothelial carcinoma and PD-L1 testing
The phase I study of atezolizumab in mUC was initially
designed to include PD-L1-positive enriched cohorts,
with a dose expansion cohort for all mUC patients
regardless of PD-L1 status [6]. The Ventana IHC assay
using the SP142 antibody (Ventana, AZ, USA) was used
for PD-L1 assessment. Here, PD-L1 positivity was
defined as IHC 2+ (≥5%) or 3+ (≥10%) PD-L1 expression
on tumor cells or tumor infiltrating immune cells
(including macrophages, dendritic cells, and lympho-
cytes). Forty-three percent (13/30) of patients with a
positive PD-L1 tumor had an objective response to
atezolizumab compared with only 11% (4/35) of patients
with negative PD-L1 status, suggesting that PD-L1 IHC
status might predict treatment response (Table 1).
Following these results, several studies were conducted
to confirm the anti-tumor activity of PD-L1 and PD-1
inhibitors in two distinct populations: patients with
mUC who had progressed after platinum-based therap-
ies and patients with mUC who were not candidates for
first-line platinum-based therapies.
Post-platinum mUC population
IMvigor 210 (Cohort 2) and KEYNOTE-045 explored
the use of atezolizumab and pembrolizumab, respect-
ively, in the post-platinum mUC population. IMvigor
210 enrolled patients with locally advanced or mUC
refractory to cisplatin-based chemotherapy. The SP142
rabbit antibody IHC assay was used to assess PD-L1
status in archival specimens as discussed above; PD-L1
positivity was defined as ≥10% PD-L1 positive immune
cells in the tumor microenvironment (defined as 3+ in
the phase I study of atezolizumab). While the objective
response rate (ORR) of the entire cohort was 15%, the
ORR was 26% (26/100) in PD-L1 positive patients,
compared with only 9% (19/210) in PD-L1 negative
patients (Table 1). These results seemed to confirm
earlier studies showing the potential for PD-L1 as a
predictive marker in mUC. Based on these results the
Phase III IMvigor 211 trial randomized patients to
atezolizumab or chemotherapy (paclitaxel, docetaxel or
vinflunine) [7] with a primary endpoint of overall
survival (OS) in PD-L1 positive subjects. The secondary
endpoint of OS in the intention-to-treat (ITT) popula-
tion was analyzed after the initial subset of PD-L1
positive cohort. While the ORR for the PD-L1 enriched
cohort was 23% compared with 13% in the ITT cohort
and confirmed prior findings, somewhat surprisingly, for
the high PD-L1cohort there was no statistical difference
in mOS when comparing atezolizumab to single agent
chemotherapy (HR: 0.87; OS: 11.1 vs 10.6 months; p =
0.41) [7]. Interestingly, a significant difference in OS was
observed in the ITT analysis for all patients treated with
atezolizumab vs chemotherapy (HR: 0.85; OS: 8.6 vs
8.0 m; p = 0.038) [7]. It is still unclear why the ITT
analysis for mOS was statistically significant, whereas
the PD-L1 positive subset was not. One hypothesis is
that the PD-L1 positive cohort was a smaller sample size
and insufficiently powered to address the benefit in
mOS for this cohort. Alternatively, the use of archival
specimens may have confounded the true assessment of
which patients were PD-L1-high at the time of study
entry. Given these somewhat contradictory results, the
accelerated FDA-approval for atezolizumab in mUC did
not change after the results of IMvigor 2011, and further
investigation of atezolizumab is underway in a Phase III
study of platinum-naïve mUC patients. Based on these
findings, it may be premature to select patients for
therapy in clinical trials of CPIs based on the Ventana
SP142 assay.
PD-L1 status did not predict for response in KEYNOTE-
045 [1], a phase III trial which randomized 542 patients
with mUC to treatment with either pembrolizumab or
standard of care chemotherapy. KEYNOTE-045 utilized the
Table 1 Summary of PD-L1 assays and response rates in immune checkpoint inhibitor trials in metastatic urothelial carcinoma
Ref Population Drug Target Antibody for PD-L1
IHC Assay
Definition of PD-L1
positivity
ORR (PD-L1+) ORR (PD-L1-) ORR All Patients
[6] Post Platinum Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 43% (13/30) 11% (4/35) 26% (17/65)
[7] Post Platinum Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 23% (26/113) 10% (36/349) 13% (63/462)
[3] Post Platinum Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 26% (26/100) 9% (19/210) 15% (45/310)
[1] Post Platinum Pembrolizumab PD-1 Mouse 22C3 (Dako) CPS≥ 10%b 22% (16/74) 22% (41/186) 21% (57/270)
[5] Post Platinum Nivolumab PD-1 Rabbit 28–8 (Dako) PD-L1≥ 5% (TC) 28% (23/81) 16% (29/184) 20% (52/265)
[7] Post Platinum Durvalumab PD-L1 Rabbit SP263 (Ventana) ≥25% TC or ≥25% IC 28% (27/98) 5% (4/79) 18% (34/191)
[10] Post Platinum Avelumab PD-L1 Rabbit 73–10 (Dako) ≥5% TC 54% (7/13) 4% (1/24) 21% (8/37)
[50] Platinum Ineligible Pembrolizumab PD-1 Mouse 22C3 (Dako) CPS≥ 10%b 51% (41/80) 23% (42/185) 31% (83/265)
[12] Platinum Ineligible Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 28% (9/32) 20% (18/87) 22% (27/119)
TC tumor cells, Ref reference, IC percentage of PD-L1 positive immune cells in the tumor microenvironment, ORR overall response rate
aIHC 2 is ≥5%, IHC 3 is ≥10%
bCombined Positive Score = percentage of PD-L1 expressing tumor and infiltrating immune cells relative to the total number of tumor cells
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22C3 mouse antibody IHC assay (Dako/Agilent, CA, USA)
using a combined positive score (CPS) to define PD-L1
positivity. The CPS was calculated as the percentage of PD-
L1 expressing tumor and infiltrating immune cells relative
to the total number of tumor cells; CPS ≥10% was consid-
ered PD-L1 positive. The ORR for all patients was 22%, and
there was no difference between patients with CPS ≥ 10%
compared with patients with a CPS < 10%. Thus, CPS was
not predictive of response to treatment with pembrolizu-
mab in this patient population. This result was in direct
contrast to the data in non-small cell lung cancer (NSCLC),
where CPS ≥ 50% does correlate with response to pembroli-
zumab [8]. More importantly, PD-L1 appeared to be a
marker of poor prognosis, with patients who were PD-L1+
having poorer outcomes compared to patients who were
PD-L1 negative by the CPS score, regardless of whether
they received chemotherapy or pembrolizumab.
While patients with a positive Ventana SP142 PD-L1
test were almost three times more likely to respond to
atezolizumab than those who were PD-L1 negative in
IMvigor 210, the absolute difference in ORR between
PD-L1 positive versus PD-L1 negative patients was not
as large as seen in the phase 1 atezolizumab study.
Furthermore, Dako 22C3 PD-L1 expression did not
appear to be associated with any treatment response for
pembrolizumab in KEYNOTE-045. Assuming that ate-
zolizumab and pembrolizumab have similar clinical
activity, it is worth exploring why, PD-L1 “positive”
patients are not the same, and why these biomarkers
may not have sufficient discriminatory power to predict
response to a CPI. As discussed above, these IHC assays
used completely different antibodies, and moreover, the
assay characteristics define PD-L1 positivity based on
staining different cellular populations (tumor cells versus
immune cells versus tumor and immune cells). Yet
another discrepancy includes the percentage of positive
cells for the threshold of positivity within the assay.
Three additional CPIs have now been studied in and
received accelerated FDA approval for the platinum-
refractory population of mUC – nivolumab, durvalumab,
and avelumab [5, 9, 10]. In the CheckMate 275 phase II
trial of nivolumab, PD-L1 status was determined using
the 28–8 rabbit antibody (Dako/Agilent, CA, USA). PD-
L1 positive patients had a ORR of 28% (23/81) compared
with an ORR of 16% (29/184) for PD-L1 negative
patients [5]. For durvalumab and avelumab, the ability
to predict the responders was somewhat greater, but in
smaller, earlier phase studies. For durvalumab, a positive
PD-L1 status (using the SP263 rabbit antibody, Ventana,
AZ, USA) was defined as ≥25% of tumor cells or tumor
infiltrating immune cells expressing PD-L1. Patients
who met this definition had an ORR of 18% (27/98),
compared with 5% (4/79) of patients who had a negative
PD-L1 [4]. For avelumab, a positive PD-L1 status was
defined as >5% PD-L1 expression by 73–10 rabbit
antibody IHC (Dako/Agilent, CA, USA) on tumor cells
[10]. The ORR was 54% (7/13) in the PD-L1 positive
group, compared with 4% (1/24) in the PD-L1 negative
group. While the use of PD-L1 as a predictive biomarker
looks promising in these two studies, these were small
studies, using different PD-L1 assays with different
thresholds defining PD-L1 positivity. The difference in
the prevalence of PD-L1 positivity across the trials
suggests that different populations of “PD-L1 positive”
patients are being captured by the different assays,
which is further complicated by the different thresholds
for positivity.
For example, in the durvalumab trial, 51% of patients
were defined as PD-L1 positive, compared with only 16%
of patients in the avelumab trial [4, 10]. This underscores
the complexity of attempting cross-trial comparisons. In
addition to different PD-L1 criteria, this may also be due
to different inclusion criteria – the avelumab trial required
at least one previous line of treatment but the durvalumab
trial did not. As clinical development moves forward for
each of these agents, further assay standardization, test
characteristics, definitions of the “biomarker-positive”
population all need to be addressed.
Platinum ineligible mUC
Due to a variety of factors, including renal or hearing
impairment, poor performance status, and neuropathies,
30% to 50% of patients with chemotherapy-naïve advanced
UC are not candidates for platinum-based chemotherapy
[11]. Cohort 1 of IMvigor 210 and KEYNOTE-052 explored
the use of atezolizumab and pembrolizumab, respectively,
in platinum-ineligible patients with mUC. Using the SP142
Ventana assay, PD-L1 positive patients in IMvigor 210 had
an ORR of 28% (9/32) compared to 20% (18/87) in those
who were PD-L1 negative [12]. Thus, the difference in
ORR between PD-L1 positive and PD-L1 negative patients
was minimal. In KEYNOTE-052, PD-L1 (with the 22C3
assay) appeared to be associated with higher response rates:
51% (41/80) of patients with a CPS ≥ 10% had an objective
response compared with 23% (42/185) of patients with a
CPS < 10% [13]. It should be emphasized that these studies
in chemotherapy-naïve, cisplatin ineligible patients were
both single-arm phase II studies, and assessment of the
predictive capacity of PD-L1 would be better explored in
appropriately powered Phase III studies. The disparate
results again suggest that a single PD-L1 score is not suffi-
cient to predict the population of patients who will respond
to immune CPIs. Multiple Phase III studies are underway
(JAVELIN bladder 100 with avelumab [NCT02603432],
IMvigor 130 with atezolizumab [NCT02807636], and DAN-
UBE with durvalumab and tremelimumab [NCT02516241])
and will further explore the predictive and prognostic
capacity of PD-L1.
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Based on the data presented above, in which patients
with mUC may respond to PD-1/PD-L1 blockade even if
their archival tumor lacks PD-L1 expression, we do not
recommend PD-L1 clinical testing in UC patients. While
in some studies PD-L1 positivity may identify patients
more likely to have an objective response, and combined
tumor/microenvironment testing may further enrich for
responders, in others studies this biomarker has no
discriminatory power, and given the conflicting results
treatment with a CPI should not be withheld based on
PD-L1 status in mUC. Prospective studies of PD-L1 as a
predictive biomarker are needed, with consideration for
contemporary/recent biopsies, tumor heterogeneity
assessments, and expression in tumor vs normal
immune cells.
Renal Cell Carcinoma (RCC)
Nivolumab received FDA approval for the treatment of
patients with advanced RCC refractory to first-line
vascular endothelial growth factor (VEGF) inhibitors,
demonstrating improved OS compared to everolimus
(median OS 25 vs 19.6 months, HR 0.73, p = 0.002) [14].
Tumor PD-L1 membrane expression was assessed using
the 28–8 Dako assay, and positivity was defined with 2
separate cut-offs as either ≥1% or ≥5% of tumor
cells (Table 2). PD-L1 expression was prognostic of sur-
vival – those with higher PD-L1 expression had poorer
survival than those with lower PD-L1 expression. Me-
dian OS was 21.8 months for patients with ≥1% PD-L1
expression compared with 27.4 months for patients <1%
PD-L1 expression in each nivolumab-treated cohort
[14]. Nivolumab improved median OS in all patients
compared to everolimus, regardless of PD-L1 status [15].
Therefore, PD-L1 was not a reliable predictive bio-
marker of treatment response. An interesting observa-
tion, however, is that many poor risk and sarcomatoid
tumors have high levels of PD-L1 expression in their
archival tumors, and this subset of patients actually had
the greatest relative benefit with nivolumab over everoli-
mus [16, 17]. These data suggest that aggressive clear
cell RCC tumors upregulate PD-L1 and may be more
vulnerable to checkpoint blockade.
Atezolizumab has also been investigated in mRCC.
The expansion cohort of a phase Ia trial enrolled 70
patients with treatment refractory mRCC; all patients
were treated with atezolizumab [18]. Enrollment started
with all patients regardless of PD-L1 status, but was later
limited to tumors which expressed PD-L1 IC2 or IC3
(≥5% IC positive for PD-L1) by the SP142 Ventana assay.
The number of patients in the trial was small but those
defined as having increased PD-L1 expression had a
higher ORR than those lacking PD-L1 expression
(18% vs 9%, Table 2).
Atezolizumab has also been investigated in the
frontline setting in combination with bevacizumab, a
VEGF inhibitor [19]. Bevacizumab had demonstrated
efficacy previously with immunotherapy, in combin-
ation with interferon alpha-2a (IFNa) among a
population of untreated mRCC. The combination
improved PFS in two major clinical trials, AVOREN
and CALGB 90206 [20, 21]. IMmotion 150 was a
phase II trial for untreated mRCC in which patients
were randomized to atezolizumab in combination
with bevacizumab, atezolizumab alone, or sunitinib.
Patients were allowed to crossover to the combination
arm after disease progression on either atezolizumab
or sunitinib. PD-L1 expression was measured based
on the Ventana SP142 IHC assay, and patients with a
PD-L1 expression ≥1% were considered PD-L1
positive. The ORR in the combination arm among
PD-L1 positive patients was 46% compared to 28% in
the atezolizumab arm alone, and 27% in the sunitinib
arm. The hazard ratios for the combination arm
compared with sunitinib were 0.64 (95%CI 0.38–1.08,
p = 0.095) and 1.03 (95%CI 0.63–1.67, p = 0.917) for
the atezolizumab alone vs sunitinib arm. Early phase
trials combining immune checkpoint inhibitors with
small molecule VEGF receptor inhibitors inpatients
enrolled regardless of PD-L1 status have shown prom-
ising results with ORRs ranging from 67% to 100%.
These studies demonstrate a signal for potentially im-
proved overall response rates for patients treated with
combination therapy. Several phase III studies are
currently underway investigating checkpoint inhibitors
Table 2 Summary of assays and response rates in immune checkpoint inhibitor trials in metastatic renal cell carcinoma
Ref CPI Drug Target Antibody for PD-L1
IHC Assay
Definition of PD-L1
positivity
ORR (PD-L1+) ORR (PD-L1-) ORR All
Patients
[14] Single Agent Nivolumab PD-1 Rabbit 28–8
(Dako)
PD-L1≥ 5% (TC) 45% (13/29) 18% (14/78) 25% (27/107)
[18] Single Agent Atezolizumab PD-L1 Rabbit SP142
(Ventana)
IHC 1/2/3 ICa 18% (6/33) 9% (2/22) 15% (8/55)
[25] Combinationb Nivolumab and
Ipilimumab
PD-1 and CTLA-4 Rabbit 28–8
(Dako)
PD-L1≥ 1% (TC) 58% (58/100) 37% (105/284) 42% (163/384)
TC tumor cells, IC percentage of PD-L1 positive immune cells in the tumor microenvironment, ORR overall response rate
aIHC 1 is ≥1%, IHC 2 is ≥5%, IHC 3 is ≥10%
bIMDC Intermediate/poor risk
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in combination with VEGF-targeted therapy for patients
with mRCC [22–24].
Immunotherapy CPI combinations have proven
effective in melanoma, and CheckMate-214 was the first
in mRCC to use combination of CTLA-4 and PD-1
inhibitors. CHECKMATE 214 was a phase III trial which
randomized 1040 patients with metastatic clear cell RCC
to treatment with either combination nivolumab-
ipilimumab or sunitinib. Co-primary endpoints included
ORR, progression free survival (PFS), and OS, specific-
ally in the IMDC intermediate or high risk population.
Secondary endpoints included PFS and OS for the
intention to treat population (including favorable risk).
Nivolumab-ipilimumab improved both median OS (not
reached (NR) vs 26.0 months, HR 0.63, p < 0.0001) and
ORR (42% vs. 27%, p < 0.0001) in patients with
intermediate-high risk disease [25]. PD-L1 positivity was
defined using the 28–8 assay (Dako/Agilent, CA, USA)
as >1% of tumor cells. In the IMDC intermediate or high
risk patients, ORR was 37% in PD-L1 negative patients
58% and PD-L1 positive patients (Table 2) [25]. In the
PD-L1 negative patients with IMDC intermediate or
high risk, PFS did not differ between those treated with
nivolumab-ipilimumab versus sunitinib (HR 1.00, p =
0.98), whereas in PD-L1 positive population, there was a
large difference in PFS between these two groups (HR
0.48, p = 0.0003) [25]. However, both PD-L1 positive and
PD-L1 negative patients benefited with improved overall
survival. Therefore, PFS was not a good surrogate
endpoint for survival benefit in the PD-L1 negative
cohort. Given the small difference in response rates in
PD-L1 positive versus PD-L1 negative patients, as well
as the improvement in mOS for these patients, the role
for PD-L1 testing remains unclear – negative PD-L1
status would not necessarily select patients who would
not benefit from nivolumab-ipilimumab. Indeed, in the
IMDC favorable risk group, ORR favored sunitinib over
nivolumab-ipilimumab (52% vs. 29%, p = 0.0002) [25].
Further data needs to be presented regarding PD-L1
status in patients with favorable risk disease, and their
survival analyses. For now, however, PD-L1 status is
not clinically useful in informing treatment decisions
in mRCC.
Further correlative work has also emphasized the
ineffectiveness of PD-L1 as a predictive biomarker in
mRCC [26]. Primary tumor and metastatic tumors have
discordant PD-L1 expression – in one pathology-based
study, discordant PD-L1 expression was detected in 21%
(11/53) of cases, suggesting that analysis of metastatic
biopsies may be necessary to form an accurate assess-
ment of PD-L1 expression [27]. Moreover, PD-L1
expression is dynamic and can arise after treatment as a
form of treatment resistance [28]. This further empha-
sizes the inadequacy of archival tissue to assess such a
dynamic biomarker. Based on the data above, at this
time, we do not recommend PD-L1 clinical testing in
metastatic RCC give the lack of clear predictive value in
any clinical setting.
PD-L1 as a biomarker
The clinical trials for mUC and mRCC mentioned above
highlight the numerous challenges facing PD-L1 as a
biomarker. First, there is no standardized format to
assess PD-L1 immunohistochemically. Several pharma-
ceutical companies have established partnerships with
diagnostic companies to design companion PD-L1
assays. These assays are in a sense more different than
they are similar. The only similarity between the assays
is that they are all IHC tissue-based assays to detect
membrane expression of PD-L1. Critical differences
include which components are included for the purposes
of scoring (tumor cells vs. immune cells), as well as
staining thresholds to define PD-L1 positivity [29]. Thus,
individual patients may have discordant results depend-
ing on the assay. This is evident when examining the
data supporting the use of durvalumab for post-
platinum UC patients. When the authors defined PD-L1
positivity by only one component, immune cells (IC) or
tumor cells (TC), there did not appear to be a clean
separation between the responders and non-responders
[9]. However, when PD-L1 status was defined by both
components (≥25% expression in either IC or TC), a
clear demarcation between responders and non-
responders emerged. This suggests that perhaps a better
predictive marker may be incorporating both PD-L1
status from both IC and TC, rather than using one
by itself.
Second, because these clinical trials have used different
companion diagnostic assays, we are unable to indirectly
compare the effectiveness of one drug in a “PD-L1
positive” population compared to another drug in a
“PD-L1 positive” population. The first two concerns have
been ameliorated in the diagnostic testing for non-small
cell lung cancer (NSCLC). Ratcliffe et al. studied the
concordance between three commercially available PD-
L1 IHC assays for NSCLC patients including Ventana
SP263 (durvalumab), Dako 22C3 (pembrolizumab), and
Dako 28–8 (nivolumab) and found >90% concordance at
several levels (1%, 10%, 25%, 50%) of PD-L1 expression
[30]. The separate Blueprint PD-L1 study also studied
the 4 different PD-L1 antibody assays in NSCLC, scored
independently by three expert pathologists. However, the
authors showed that PD-L1 status would have been
classified differently depending on PD-L1 assay in 37%
(14 of 38) of the cases [31]. This data suggest that these
assays may be used to aid in the therapeutic decision
making for a NSCLC population, but they may have
variable concordance in defining PD-L1 positivity. Similar
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studies to compare the PD-L1 assays have not been
performed in advanced UC or RCC.
Lastly, there are both biological and technical chal-
lenges which further complicate PD-L1 testing. This
has been well reviewed in the literature [32, 33].
Biological challenges include intratumoral and intertu-
moral heterogeneity of PD-L1 expression, a temporal
evolution of PD-L1 status particularly during the devel-
opment of treatment resistance, and variation in PD-L1
expression according to the level of tissue hypoxia [27].
PD-L1 is particularly dynamic and the use of archival
specimens for assigning PD-L1 status severely limits
the classification of patients at the time of treatment.
PD-L1 status in the archival specimen may not reflect
the true PD-L1 status of a patient when started on CPI
treatment. Technical challenges include variation in PD-
L1 expression due to time in formalin, variation in the
affinity of the anti-PD-L1 antibody, and standardization of
the systems for amplification and discordance be-
tween assay definitions on what constitutes a positive
PD-L1 signal.
Biomarkers beyond PD-L1
There are several other predictive biomarkers under
examination for mUC and mRCC, including tumor
mutational burden (TMB), mismatch repair status, gene
expression profiles (GEP), TCGA (The Cancer Genome
Atlas) profiling, tumor infiltration lymphocytes (TILs),
and PD-L2.
Tumor mutational burden and MSI status
It has been observed that tumors with a higher muta-
tional burden may have a better response to immuno-
therapy [34]. Higher tumor mutational burden (TMB) is
theoretically associated with increasing neo-antigens that
may be better recognized by the immune system. A high
prevalence of insertions/deletions (indels) may also be
predictive of IC response due to associations with
neoantigen load in RCC, suggesting that the specific
types of genomic alterations in tumors may be critically
important for antigen presentation and recognition [35].
In mUC, data from IMvigor 210 further suggest that
high TMB may not be only prognostic of survival, but
potentially predictive of response [3, 13]. Patients in the
highest quartile of TMB had a significantly longer mOS
when treated with atezolizumab compared with those in
quartiles 1–3 (p = 0.0041) [13]. TMB did not correlate
with TCGA subtype, immune cell subgroups, or smoking
history. High TMB patients have also been shown in
Checkmate 275 to have a better ORR (31.9% vs 17.4%, p =
0.002) and median PFS (3.02 months vs. 1.87 months)
[36]. Recently, high TMB was also found in mUC patients
who also harbored ERBB2 (HER2) and ERBB3 (HER3)
mutations [37]. These data suggest targets for rational
combinations of mUC-targeting treatments. These data
suggest that TMB can potentially predict for treatment
responses to immune CPIs, but more prospective studies
are needed to elucidate its true predictive role.
Not surprisingly, patients with the highest mutational
burden often harbor specific DNA damage response
defects, such as microsatellite instability (MSI-H) or are
mismatch repair deficient (dMMR) [38]. Thus, clinical
trials enriching for this population have found that
patients with mismatch repair defects have some of the
highest response rates to PD-1 blockade [39]. Based on
the cumulative data from five clinical trials totaling 149
patients, the FDA has approved pembrolizumab for
tumors that have been identified as MSI-H or dMMR
[40]. This tumor agnostic approval of pembrolizumab
was the first of its kind. Based on data from five KEY-
NOTE trials, pembrolizumab had an overall response
rate of 40% amongst the population who were identified
as MSI-H and dMMR, and it is worth noting that 78%
of the patients who responded had a response rate of
6 months or longer [39, 41]. MSI-H a major feature of
patients with HNPCC or Lynch syndrome (Hereditary
Nonpolyposis Colorectal Cancer). While colon and
endometrial cancer are the two most common HNPCC
associated cancers, upper tract urothelial carcinomas
(UT-UC) rank third, with a prevalence of 5% [42, 43].
For patients with UT-UC, further history should be
obtained to elucidate their risk factors for Lynch
syndrome, and if appropriate, proceed with genetic
counseling and testing.
Gene expression profiles (GEP)
Gene expression profiling has demonstrated utility as a
predictive biomarker to chemotherapy and immunother-
apy [44–47]. The expression of interferon gamma is one
of the key biomarkers that has been explored as a
predictive biomarker for these agents. When abnormal
cellular growth occurs as a result of exposure to
radiation, smoking, or chronic viral infections, the innate
and adaptive antitumor response is initiated which leads
to the production of interferon gamma. Interferon
gamma is produced by activated T cells, natural killer
cells (NK) cells, the tumor microenvironment, and can
lead to upregulation of both PD-L1 and PD-L2. Through
a feedback loop, interferon gamma can also upregulate
the expression of immunosuppressive molecules such as
IDO1. Thus, interferon gamma is key in protecting the
host from developing tumors, but it also facilitates tumor
escape mechanisms from the immune system [48].
Ayers et al. evaluated 680 tumor and immune related
genes using a NanoString nCounter platform and found
that the genes most able to separate responders from
non-responders of PD-1 therapy were genes linked to
interferon gamma signaling [49]. The initial panel of
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genes was developed based on a small cohort of melan-
oma patients but was further expanded using a data set
spanning nine cancer types, which ultimately resulted
in an 18 GEP which could predict response to pembro-
lizumab across multiple solid tumors. This GEP was
used in the trial examining pembrolizumab in the first
line platinum ineligible UC population [50]. The
authors found that the GEP score was significantly
associated with a treatment response (p < 0.0001). GEP
score could correctly predict 70 of the 81 responders,
compared to the PD-L1 CPS cutoff, which predicted
only 41 of the 81 responders. While this is hypothesis
generating, the utility of GEP still needs to be validated
in large prospective clinical trials.
Intrinsic molecular subtypes
Consensus clustering based on gene expression data
from TCGA has distinguished two major intrinsic
subtypes of high grade bladder cancer – luminal and
basal [51]. Rosenberg et al. explored the link between
these unique molecular subtypes of bladder cancer and
their response to PD-L1 inhibition [3]. Basal subtype
tumors had increased PD-L1 tumor cell expression (39%
in basal vs 4% in luminal, p < 0.0001) and increased PD-
L1 immune cell prevalence (60% vs 23%, p < 0.0001).
However, the increase of PD-L1 expression in the basal
subtype did not correlate with an objective response.
Response to atezolizumab in this post-platinum popula-
tion was much higher in the luminal cluster II subtype
compared with all other subtypes. This relationship was
again observed in the front line platinum-ineligible
population with the luminal II samples having a higher
response rate compared to the other molecular subtypes
– however, the sample size was not sufficient to reach
statistical significance [12]. Further studies are necessary
to confirm if luminal cluster II may be a predictive bio-
marker of response.
PD-L2
PD-L2 is another ligand capable of binding to PD-1.
While its structure is quite similar to PD-L1, the exact
function of PD-L2 is controversial [52]. PD-L2 plays a
role in regulating T cell immune response and immune
tolerance - some studies have shown that PD-L2 is an
inhibitory co-stimulatory molecule whereas others have
shown that it is a positive costimulatory molecular that
functions through a different receptor than PD-1 [53,
54]. What is known, however, is that the expression
pattern of PD-L1 and PD-L2 is distinct, that both PD-L1
and PD-L2 compete to bind to PD-1, and that PD-L2
may be capable of binding to other receptors in addition
to PD-1 [55].
In RCC, while PD-L1 expression was observed in only
9% of cases in a series of 425 patients, PD-L2 expression
was observed in 50% of cases [56]. PD-L1 and PD-L2
were evaluated retrospectively amongst a cohort of 20
selected patients – 8 patients who had a durable clinical
benefit (DCB) for more than 12 months and 12 patients
with limited clinical benefit (LCB), defined as less than
6 months of benefit [26]. As a predictive biomarker,
when PD-L1 or PD-L2 were analyzed separately, there
did not appear to be an association with clinical benefit
– however, when analyzed together, a significant associ-
ation was found when using a PD-L1 cutoff score of 1%
and PD-L2 cutoff score of 5%. 88% (7/8) of the DCB
cohort met this metric of being positive for either PD-L1
or PD-L2, or both, compared to 36% (4/11) of the LCB
group for the same metric [26]. The ability for PD-L2 to
predict response has also been demonstrated in
NSCLC [57]. Larger studies are necessary to validate
this relationship.
Tumor infiltrating cytotoxic T lymphocytes (TILs)
CPIs are known to enhance the activity of the adaptive
immune system by recruiting CD8 positive cytolytic T
cells into the tumor microenvironment [58]. CD8
positive T cell density and CD8 positive density at the
invasive margin, as well as clonality within the T-cell
repertoire have been previously described as predictive
biomarkers for response to CPI therapy in metastatic
melanoma [58]. A special population of CD8 positive T
cells have been identified as “partially exhausted”
cytotoxic T lymphocytes (peCTL), which are tumor-
infiltrating CD8+ T cells which express high levels of
cytotoxic T lymphocyte–associated antigen 4 (CTLA-4)
[59]. peCTLs have been shown to strongly correlate with
response to anti-PD1 therapy in metastatic melanoma
[59, 60]. Interestingly, while high levels of peCTLs are
associated with a response in anti-PD1 therapy, a lower
peCTL level was correlated with a higher ORR with
combination immunotherapy. This suggests that peCTL
levels may be useful when deciding between single or
combination immunotherapy in the future.
High T cell infiltration and clonality in advanced UC
has also correlated with treatment response [58].
Increased TILs within the tumor microenvironment,
particularly in UC, have been found to correlate with
improved disease free survival and overall survival [61].
In a retrospective evaluation of 31 patients with muscle
invasive UC, patients with more than 8 CD8 TILs had a
median survival of more than 80 months, compared to a
median survival of 13 months for those with less than 8
CD8 cells [61]. In IMvigor 210 of atezolizumab in
platinum-refractory mUC, the inflammatory CD8
cytotoxic T-cells within the tumor microenvironment
was associated with objective response to atezolizumab
(p = 0.0265) [3]. These tests are more cumbersome but
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may ultimately prove to be more useful as biomarkers
for response to CPI therapy.
Composite immune biomarkers
Ultimately, a single biomarker may not adequately
predict response to PD-1 immune checkpoint therapies,
and a combination of factors may need to be taken into
account to predict responses. Based on the level of
CD8A and PD-L1 expression, Ock et al. described four
distinct tumor microenvironment immune types (TMIT)
[62]. Tumors with an elevated CD8A and PD-L1 expres-
sion were grouped as Type I TMIT. Type I TMIT
tumors had a significantly higher mutational burden
compared with the other types of tumors, higher
number of neoantigens, and were also associated with
PD-L1 amplification, all characteristics which imply
responsiveness to PD-1 and PD-L1 inhibition. This
suggests that TMIT may be a more comprehensive score
as a predictive biomarker for these CPIs. Prospective
clinical trials using the TMIT framework are necessary.
These types of composite assessments which combine
multiple biomarkers within the same platform are
currently in development. A concern about using
composite biomarker panels, however, is both their
clinical utility (will it be feasible to wait for multiple
assays to return before starting CPI therapy?) as well
as increased costs associated with multi-omic and
IHC profiling.
Gastrointestinal microbiome
It is well established that the gut microbiota plays a
critical role in both innate and adaptive immune homeo-
stasis [63]. Thus, it would be reasonable to suspect that
the fecal microbiome may contain potential predictors
of CPI as well as predictors of CPI induced colitis. Both
of these questions have been investigated. In germ-free
or antibiotic treated mouse models, CTLA-4 blockade
was ineffective at preventing tumor progression [64].
However, after re-colonization of germ free or antibiotic
treated mice with several bacterial species including B.
fragilis, the mice were able to recover an anticancer
response to CTLA-4 blockade. This finding is similar to
that reported by Sivan et al., which found that the best
responses to PD-L1 blockade required specific Bacter-
oides - mice which were given oral Bifidobacterium
improved tumor control to the same degree as those
given an anti-PD-L1 agent [65]. With regards to predict-
ing tumor toxicity, Dubin et al. have discovered that the
presence of specific microbiota phylotypes can help
predict a patient’s risk of developing colitis following
CTLA-4 blockade [66]. These studies suggest that the
further research on the gastrointestinal microbiome may
yield biomarkers for predicting response and provide
strategies to maximize clinical benefit.
Conclusion
The FDA approval of several checkpoint inhibitors for
the treatment of mUC and mRCC represents a major
landmark for patients and oncologists. However, it is
critical that we choose the right patients, given that
these drugs have the potential for not only physical
toxicity but also financial toxicity, with costs of up to
$20,000 per month [67]. Selecting patients who will
respond to PD-1 and PD-L1 blockade remains a
challenge. Data from the clinical trials which led to the
approvals of PD-1 and PD-L1 directed therapies in mUC
and mRCC show that the use of PD-L1 expression alone
is insufficient and inefficient at predicting treatment
response. The future of predictive biomarkers likely
involves a combination of many biologic variables, some
of which have been mentioned above. Of these, tumor
mutational burden shows promise in predicting for
treatment responses to immune CPIs. Ultimately, a
single biomarker may not be enough to determine
treatment response, and comprehensive biomarkers
incorporating several or all of these biomarkers are
currently in development as predictive biomarkers.
These composite biomarkers ultimately will need to be
prospectively validated in the context of therapeutic
clinical trials.
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